Invenra, Inc.
Invenra is a biotechnology company dedicated to advancing therapeutic antibody discovery and development. They focus on innovative platforms such as the B-Body® Bispecific Platform and the T-Body™ Trispecific Antibody Platform to create high-yield, stable, and effective bispecific and trispecific antibodies. Their mission is to enable the discovery of novel therapies across various disease categories, with a strong emphasis on oncology. Invenra offers flexible solutions including rapid discovery services, collaborative development partnerships, and a comprehensive pipeline of antibody candidates aimed at improving patient health.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Bispecific antibody engineering platform optimized for high yield and CMC compatibility
A human IgG-like platform architecture engineered for high expression yield, correct heterodimer assembly, single-step affinity purification for discovery, and compatibility with conventional CMC downstream processes and subcutaneous formulation requirements.
Trispecific antibody engineering platform for multi‑antigen engagement
An antibody architecture engineered to integrate three antigen-binding arms into an IgG-like structure using domain engineering to enable simultaneous binding to three distinct targets and to facilitate high expression, assembly, and purification.
Bispecific antibody engineering platform optimized for high yield and CMC compatibility
A human IgG-like platform architecture engineered for high expression yield, correct heterodimer assembly, single-step affinity purification for discovery, and compatibility with conventional CMC downstream processes and subcutaneous formulation requirements.
Trispecific antibody engineering platform for multi‑antigen engagement
An antibody architecture engineered to integrate three antigen-binding arms into an IgG-like structure using domain engineering to enable simultaneous binding to three distinct targets and to facilitate high expression, assembly, and purification.
Services
Parallel functional screening of large combinatorial bispecific panels to generate lead panels on a 2–4 month timeline; includes downstream expression in multiple formats for follow-up testing.
Research-scale antibody expression services producing two-step purified samples (small volumes) within accelerated timelines to support early-stage evaluation.
Strategic, integrated partnerships offering custom antigen design, assay development, biological analysis, expression in multiple formats, and support for large-scale preclinical studies.
Parallel functional screening of large combinatorial bispecific panels to generate lead panels on a 2–4 month timeline; includes downstream expression in multiple formats for follow-up testing.
Research-scale antibody expression services producing two-step purified samples (small volumes) within accelerated timelines to support early-stage evaluation.
Strategic, integrated partnerships offering custom antigen design, assay development, biological analysis, expression in multiple formats, and support for large-scale preclinical studies.
Expertise Areas
- Multispecific antibody engineering
- Antibody discovery and high-throughput functional screening
- Mammalian cell expression and cell line development
- Downstream purification and CMC development
Key Technologies
- CHO and HEK mammalian expression systems
- Transient and stable cell line expression
- Fed-batch and perfusion bioreactors
- Protein A and ion-exchange chromatography
News & Updates
Invenra announced the initiation of a Phase 1 clinical study evaluating XB628, a first-in-class bispecific antibody, in participants with recurrent advanced or metastatic solid tumors.
Invenra announced the launch of its T-Body™ Trispecific Antibody Platform designed to target three distinct antigens simultaneously, enhancing therapeutic potential.
Invenra introduced B-Body Express™, a service that provides rapid access to their bispecific antibody platform, delivering purified antibodies in 8 weeks.
Invenra announced the initiation of a Phase 1 clinical study evaluating XB628, a first-in-class bispecific antibody, in participants with recurrent advanced or metastatic solid tumors.
Invenra announced the launch of its T-Body™ Trispecific Antibody Platform designed to target three distinct antigens simultaneously, enhancing therapeutic potential.
Invenra introduced B-Body Express™, a service that provides rapid access to their bispecific antibody platform, delivering purified antibodies in 8 weeks.